Temtokibart clinical trials
Also written LEO 138559.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses temtokibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LEO 138559
- 5
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses temtokibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic DermatitisCompletedPhase 2LEO PharmaNCT05923099Written as LEO 138559How we know
- An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.CompletedPhase 2LEO PharmaNCT04922021Written as LEO 138559How we know
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe ADCompletedPhase 2LEO PharmaNCT05470114Written as LEO 138559How we know
- Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic DermatitisCompletedPhase 1LEO PharmaNCT03514511Written as LEO 138559How we know
- A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese SubjectsCompletedPhase 1LEO PharmaNCT05099133Written as LEO 138559How we know
Codes
What other systems call temtokibart · ClinicalTrials.gg INT018192
- UNII (FDA) V2XME9F5SFTEMTOKIBARTOne source FDA
- NCI Thesaurus C199119TemtokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V2XME9F5SF | TEMTOKIBART | One source FDA |
| NCI Thesaurus | C199119 | Temtokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.